Cargando…

Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis

PURPOSE: The aim of this study was to identify positive predictors for survival in uveal melanoma (UM) patients treated with percutaneous hepatic perfusion with melphalan (M-PHP), by retrospectively pooling data from three centers. MATERIALS AND METHODS: Retrospective analysis including patients ([F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tong, T. M. L., Samim, M., Kapiteijn, E., Meijer, T. S., Speetjens, F. M., Brüning, R., Schroeder, T. H., El-Sanosy, S., Maschke, H., Wacker, F. K., Vogel, A., Dewald, C. L. A., Goeman, J. J., Burgmans, M. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458688/ https://www.ncbi.nlm.nih.gov/pubmed/35922562 http://dx.doi.org/10.1007/s00270-022-03225-9

Ejemplares similares

Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience
por: Dewald, Cornelia L. A., et al.
Publicado: (2021)

ASO Author Reflections: Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Hepatic Metastases from Ocular Melanoma
por: Meijer, T. Susanna, et al.
Publicado: (2020)

Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study
por: Meijer, T. Susanna, et al.
Publicado: (2020)

Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer
por: Meijer, T. Susanna, et al.
Publicado: (2022)

Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery
por: Dewald, C. L. A., et al.
Publicado: (2020)

Percutaneous Isolated Hepatic Perfusion for the Treatment of Unresectable Liver Malignancies
por: Burgmans, Mark C., et al.
Publicado: (2015)

Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden
por: Brüning, R., et al.
Publicado: (2020)

Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial
por: Meijer, T. Susanna, et al.
Publicado: (2019)

Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma
por: Modi, Sachin, et al.
Publicado: (2022)

Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
por: de Leede, Eleonora M., et al.
Publicado: (2017)

Erratum to: Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
por: de Leede, Eleonora M., et al.
Publicado: (2017)

New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option
por: Dewald, Cornelia L. A., et al.
Publicado: (2022)

Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial
por: Tong, T. M. L., et al.
Publicado: (2022)

Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types
por: van der Kooij, Monique K., et al.
Publicado: (2019)

Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease
por: Karydis, Ioannis, et al.
Publicado: (2017)

Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience
por: Artzner, Christoph, et al.
Publicado: (2019)

Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.
por: Borel Rinkes, I. H., et al.
Publicado: (1997)

Isolated Limb Perfusion with Melphalan and TNF-α in the Treatment of Extremity Sarcoma
por: Verhoef, Cornelis, et al.
Publicado: (2007)

Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period
por: Tong, Thaïs M. L., et al.
Publicado: (2023)

The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.
por: Scott, R. N., et al.
Publicado: (1992)

Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases
por: van Iersel, Liselot B. J., et al.
Publicado: (2008)

Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)
por: Olofsson Bagge, Roger, et al.
Publicado: (2023)

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
por: Piperno-Neumann, S., et al.
Publicado: (2023)

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.
por: Klaase, J. M., et al.
Publicado: (1994)

The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft.
por: Wu, Z. Y., et al.
Publicado: (1997)

Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
por: Wilt, J H W de, et al.
Publicado: (1999)

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
por: de Wilt, J H W, et al.
Publicado: (2000)

Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients
por: Johansson, Junko, et al.
Publicado: (2018)

TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature
por: Podleska, L E, et al.
Publicado: (2015)

TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature
por: Podleska, L E, et al.
Publicado: (2015)

2D-Perfusion Angiography Using Carbon Dioxide (CO2): A Feasible Tool to Monitor Immediate Treatment Response to Endovascular Therapy of Peripheral Arterial Disease?
por: Dewald, Cornelia L. A., et al.
Publicado: (2020)

Depiction of mosaic perfusion in chronic thromboembolic pulmonary hypertension (CTEPH) on C-arm computed tomography compared to computed tomography pulmonary angiogram (CTPA)
por: Maschke, Sabine K., et al.
Publicado: (2021)

Factors influencing the chemosensitization of melphalan by misonidazole.
por: Randhawa, V. S., et al.
Publicado: (1985)

Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion.
por: Marinelli, A., et al.
Publicado: (1991)

Evaluation of perfusion changes using a 2D Parametric Parenchymal Blood Flow technique with automated vessel suppression following partial spleen embolization in patients with hypersplenism and portal hypertension
por: Meine, Timo C., et al.
Publicado: (2021)

Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion.
por: Kuppen, P. J., et al.
Publicado: (1997)

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
por: Moscow, J. A., et al.
Publicado: (1993)

Heparin reversal with protamine sulfate after Percutaneous Hepatic Perfusion (PHP): is less more?
por: Facchetti, Nadia, et al.
Publicado: (2023)

Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery
por: Struck, Manuel Florian, et al.
Publicado: (2021)

Evaluation of Delcath Systems’ Generation 2 (GEN 2) Melphalan Hemofiltration System in a Porcine Model of Percutaneous Hepatic Perfusion
por: Moeslein, Fred M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_at9b9kcm1h2flmbp4hb1vioqi1